Thirty-three people with obesity and psoriasis took semaglutide ↗ for 18 months, and their skin got better as their weight came down. Average psoriasis severity fell by nearly half. The problem is that nothing in the study can tell you which of those two things caused the other.
The numbers come from a retrospective review published October 16 in the Journal of Clinical Medicine ↗ by dermatologists Ilaria Proietti and Concetta Potenza at Sapienza University of Rome's Latina campus. They pulled the charts of 33 adults (24 men, 9 women) with obesity and mild to moderate psoriasis who had been on semaglutide, the active ingredient in Ozempic and Wegovy, for a year and a half.
Psoriasis severity is scored with the PASI, the Psoriasis Area and Severity Index, a 0 to 72 scale where higher means more of the body covered in thicker, redder, scalier plaque. Mild to moderate disease sits around 9. In this group the average PASI dropped from 9.31 to 5.05, a fall of 4.25 points (p less than 0.001, meaning the change is very unlikely to be chance). Over the same stretch average body mass index fell from 32.5 to 28.4, roughly the difference between clear obesity and the low end of overweight. Blood markers of inflammation dropped too. About 58 percent of patients had mild, short-lived stomach upset, and none quit the drug.
Why the skin and the scale move together
The reason this is hard to read is that obesity is not a bystander in psoriasis. Fat tissue is metabolically active and secretes signaling molecules that feed the same inflammatory pathways, interleukin-17 and tumor necrosis factor among them, that drive psoriatic plaque. Heavier patients tend to have worse psoriasis and respond less well to the antibody drugs aimed at those pathways. Take the weight off by any route and the skin often calms down on its own.
So when a patient on semaglutide loses four BMI points and their PASI halves, there are two candidate explanations sitting on top of each other. One is that the drug is doing something directly to skin inflammation through its receptor. GLP-1 receptors ↗ turn up on immune cells, not just in the pancreas and brain, and there is a real hypothesis that agonists dampen inflammation independently of weight. The other is that the weight loss did the work and the drug was just the tool that delivered it. This study has no way to pull those apart, because every patient got the same drug and lost weight. There is no comparison arm of people who lost the same weight without semaglutide, or who took semaglutide without losing weight.
The catch the authors name themselves
Proietti and Potenza are direct about the limit. The study is single-center, retrospective, has no control group, and 33 patients is small. They frame the result as a signal worth testing in a controlled trial, not as evidence that semaglutide treats psoriasis. That framing is the honest one, and it is worth repeating because the number, a psoriasis score cut almost in half, is the kind that gets stripped of its caveats on the way to a headline.
This is the mirror image of an earlier read on the same question. A patient survey we covered found that inflammatory rashes eased as GLP-1 users lost weight ↗, bundled in with the sagging skin and hair loss that heavy weight loss also brings. In some GLP-1 skin reports the weight loss has been too small to explain the improvement, which points toward a direct drug effect. Here the weight loss is large, which points the other way, or rather points nowhere, because it leaves the drug and the pounds fully entangled.
What would settle it is a trial that separates the two inputs: randomize semaglutide against a different weight-loss route to the same target BMI, and watch whether psoriasis still responds better on the drug. Until then, the fair statement is narrow. Patients with obesity and psoriasis who went on semaglutide got lighter and their skin got better, and that is a reason to run the trial, not a reason to prescribe the drug for skin.